Efficacy and safety of Cordyceps sinensis (Hirsutella sinensis, Cs-C-Q80) in chronic bronchitis.

Background: Cordyceps sinensis is a traditional Chinese medicine that has shown promise for the management of chronic bronchitis (CB). We aim to assess the efficacy and safety of a preparation of C sinensis named Bailing capsule (Hirsutella sinensis, Cs-C-Q80) compared with a placebo in patients with CB. Methods: This randomized, double-blind, placebo-controlled, parallel-group clinical trial (Chinese Clinical Trial Registry; registration number: ChiCTR1900025707) recruited patients with CB from eight hospitals in China between May 2019 and December 2020. Patients were randomized 2:1 to receive Bailing capsule or a placebo orally for 48 weeks (2.0 g, three times a day). Results: Among 240 patients who were randomized, 238 (Bailing capsule: 159, placebo: 79) were included in the primary analysis. Bailing capsule significantly reduced the frequency of acute exacerbation of CB (AECB) compared with the placebo during treatment (0.43 ± 0.82 vs. 1.56 ± 1.34; P < 0.001) and follow-up (0.21 ± 0.64 vs. 0.45 ± 0.93; P = 0.026). Bailing capsule improved the severity of expectoration (P = 0.046) and wheezing (P = 0.010) in AECB during follow-up. The severity of CB after treatment was significantly improved in the Bailing capsule group compared with the placebo group (P = 0.035), particularly in terms of expectoration (P = 0.012) and wheezing (P = 0.003). The risk of adverse events, mainly including infectious and invasive diseases and gastrointestinal symptoms, did not significantly differ between the two groups (29.6% vs. 30.4%). Conclusion: In patients with CB, Bailing capsule significantly reduces the frequency of AECB and ameliorates the severity of AECB and CB symptoms. Clinical Trail Registration: https://www.chictr.org.cn, identifer ChiCTR1900025707.

Exploring the efficacy and mechanism of Bailing capsule to improve polycystic ovary syndrome in mice based on intestinal-derived LPS-TLR4 pathway.

ETHNOPHARMACOLOGICAL RELEVANCE: Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with reproductive dysfunction and metabolic abnormalities, particularly characterized by insulin resistance and chronic low-grade inflammation. Multiple clinical studies have clearly demonstrated the significant efficacy and safety of the combination of Bailing capsules (BL) in the treatment of PCOS, but its pharmacological effects and mechanisms still require further study. AIM OF THE STUDY: To evaluate the effect of BL on improving PCOS in mice and explore the mechanism. METHODS: In this study, Dehydroepiandrosterone (DHEA) injection was administered alone and in combination with a high-fat and high-sugar diet to induce PCOS-like mouse. They were randomly divided into five groups: normal group (N), PCOS group (P), Bailing capsule low-dose group (BL-L), Bailing capsule high-dose group (BL-H) and Metformin + Daine-35 group (M + D). Firstly, the effects of BL on ovarian lesions, serum hormone levels, HOMA-IR, intestinal barrier function, inflammation levels, along with the expression of IRS1, PI3K, AKT, TLR4, Myd88, NF-κB p65, TNF-α, IL-6, and Occludin of the ovary, liver and colon were investigated. Finally, the composition of the gut microbiome of fecal was tested. RESULTS: The administration of BL significantly reduced body weight, improved hormone levels, improved IR, and attenuated pathological damage to ovarian tissues, up-regulated the expression of IRS1, PI3K, and AKT in liver. It also decreased serum LPS, TNF-α, and IL-6 levels, while downregulating the expression of Myd88, TLR4, and NF-κB p65. Additionally, BL improved intestinal barrier damage and upregulated the expression of Occludin. Interestingly, the abundance of norank_f__Muribaculacea and Lactobacillus was down-regulated, while the abundance of Akkermansia was significantly up-regulated. CONCLUSION: The results of the study showed that BL exerts a treatment PCOS effect, which may be related to the modulation of the gut microbiota, the improvement of insulin resistance and the intestinal-derived LPS-TLR4 inflammatory pathway. Our research will provide a theoretical basis for the clinical treatment of PCOS.

Clinical effect of Bailing capsule on patients after renal transplantation / 药学实践与服务

Objective To study the effect of Bailing capsule on renal function and other organ systems in 60 patients after renal transplantation in No. 910 Hospital of Joint Logistics Support Force. Methods 60 patients with renal allograft in 2018−2020 were divided into 2 groups according to different immunosuppressive regimens. In the control group, 35 cases were treated with MMF + CsA or FK506; in the treatment group, 25 cases were treated with MMF + CsA or FK506 + Bailing capsule. Blood and urine routine, liver and renal function and uric acid were measured after operation. The dosage of immunosuppressive drugs was recorded in stages at 48 weeks. Results The urinary red and white blood cell counts, blood aspartate transaminase and alanine transaminase, serum uric acid, total bilirubin and direct bilirubin in the treatment group were significantly less than those in the control group, while the serum total protein and albumin were significantly higher than those in the control group. The number of red blood cells and white blood cells in the treatment group was significantly higher than that in the control group at 12-48 weeks after kidney transplantation, and that in the lymphocyte group was significantly higher than that in the control group at 24-48 weeks after kidney transplantation. The dosage of CsA and FK506 in the treatment group was significantly lower than that in the control group after 48 weeks. Conclusion Bailing capsule could protect liver and kidney, stimulate hematopoiesis, improve hypoalbuminemia and reduce the dosage of immunosuppressant, which could be an ideal immunomodulator.

Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Bailing capsule on polycystic ovary syndrome.

BACKGROUND: Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder that is common in women of reproductive age. The clinical features of PCOS include hyperandrogenemia and polycystic ovarian changes. Bailing capsule (BL), a proprietary Chinese medicine that contains fermented Cordyceps sinensis powder, has been applied to treat PCOS. However, the specific active ingredients of BL and its mechanisms of action are yet to be elucidated. METHODS: Initially, the effectiveness of BL on PCOS model mice was evaluated. Subsequently, the active ingredients of BL were searched in the TCMSP and TCM Systems Pharmacology databases, and their targets were predicted using Swiss Target Prediction and SEA databases. Furthermore, the GEO gene database was used to screen for differentially expressed genes (DEGs) related to PCOS. Data from Gene Card, OMIM, DDT, and Drugbank databases were then combined to establish a PCOS disease gene library. Cross targets were imported into the STRING database to construct a protein-protein interaction network. In addition, GO and KEGG pathway enrichment analyses were performed using Metascape and DAVID databases and visualized using Cytoscape software and R 4.2.3. The core targets were docked with SYBYL-X software, and their expressions in PCOS mice were further verified using qPCR. RESULTS: The core active ingredients of BL were identified to be linoleyl acetate, cholesteryl palmitate, arachidonic acid, among others. Microarray data sets from four groups containing disease and normal samples were obtained from the GEO database. A total of 491 DEGs and 106 drug-disease cross genes were selected. Estrous cycle and ovarian lesions were found to be improved in PCOS model mice following BL treatment. While the levels of testosterone, progesterone, and prolactin decreased, that of estradiol increased. qPCR findings indicated that the expressions of JAK2, PPARG, PI3K, and AKT1 were upregulated, whereas those of ESR1 and IRS1 were downregulated in PCOS model mice. After the administration of BL, the expressions of associated genes were regulated. This study demonstrated that BL exerted anti-PCOS effects via PIK3CA, ESR1, AKT, PPARG, and IRS1 targets affecting PI3K-Akt signaling pathways. DISCUSSION: This research clarified the multicomponent, multitarget, and multichannel action of BL and provided a theoretical reference for further investigations on its pharmacological basis and molecular mechanisms against PCOS.

Analysis of the clinical efficacy of three kinds of Chinese patent medicines assisting tacrolimus in the treatment of nephrotic syndrome / 中国临床药理学与治疗学

AIM: To explore the clinical efficacy of three different kinds of Chinese patent medicines combined with tacrolimus and hormone in the treatment of nephrotic syndrome (NS). METHODS: A total of 199 patients with NS treated in department of nephrology of our hospital from January 2018 to December 2020 were analyzed retrospectively. All patients were treated with tacrolimus combined with hormone regimen for 12 weeks. According to different treatment schemes, they were divided into 4 groups: 57 cases in the control group, 51 cases in the Bailing capsule group (Bailing group), 55 cases in the Huangkui capsule group (Huangkui group) and 36 cases in the Wuzhi capsule group (Wuzhi group). The general data of patients, the biochemical indexes before and after treatment, and the tacrolimus blood concentration were collected. RESULTS: After 12 weeks of treatment, 24 h UTP and ALB of each group were statistically different (P<0.01). Compared with the control group, Bailing group had statistically significant differences in the reduction of TG and TC (P<0.05), Huangkui group had statistically significant differences in the reduction of 24 h UTP and serum TC (P<0.05), Wuzhi group had statistically significant differences in the reduction of 24 h UTP and AST (P<0.05). The steady-state trough concentration (C

Efficacy and safety of Bailing capsules in the treatment of type 2 diabetic nephropathy: a meta-analysis.

BACKGROUND: Diabetic nephropathy (DN) is the main cause of end-stage renal failure (ESRF) in diabetic patients. Chinese medicine plays an extremely important role in controlling the symptoms of DN. At present, the efficacy and safety of Bailing capsules in the treatment of type 2 DN are still unclear. Therefore, the aim of this meta-analysis was to evaluate the clinical efficacy and safety of Bailing capsules in the treatment of type 2 DN. METHODS: A literature search on type 2 DN was conducted using Chinese and English databases. The Chinese databases searched were the CNKI database, Wanfang database, and Weipu database using the following search terms: Bailing capsule and DN. The English databases were PubMed, Embase, and Web of Science using the following search terms: type 2 diabetes mellitus, type II diabetes mellitus, and Bailing capsule. The quality of the literature was evaluated using RevMan 5.3 software. The meta-analysis was performed using the R3.5.1 software meta package. RESULTS: Twenty-four articles with a total of 985 patients in the treatment group and 956 patients in the control group were found. The total effective rate of Bailing capsules in the treatment group was 1.24 times that of the control group [95% confidence interval (CI): 1.11-1.38]. Reductions in 24-h urine total protein, urine albumin excretion rate (UAER), serum creatinine (Scr), and blood urea nitrogen (BUN) levels before and after treatment in the treatment group were significantly lower than that of the control group, with standard mean differences (SMD) of 0.61 (95% CI: -1.01 to -0.22), -1.56 (95% CI: -2.34 to -0.78), -0.58 (95% CI: -0.89 to -0.27), and -0.73 (95% CI: -1.16 to -0.29), respectively. However, there was no significant change in serum potassium between the two groups (P>0.05). No publication bias was found in the metaanalysis (P>0.05). CONCLUSIONS: For type 2 DN patients, the use of Bailing capsules in routine treatment demonstrated higher clinical efficacy and was found to improve the kidney function. However, high-quality randomized controlled trials are required to further explore the safety of Bailing capsules.

A meta-analysis of the clinical efficacy and safety of Bailing capsules in the treatment of nephrotic syndrome.

BACKGROUND: Nephrotic syndrome (NS) is extremely harmful to human health. Bailing capsules can reduce proteinuria and improve renal function in patients with NS. This meta-analysis aimed to evaluate the clinical efficacy and safety of Bailing capsules in the treatment of NS. METHODS: Systematic searches of the English-language databases PubMed, Cochrane, Embase, Medline, and Web of Science, as well as the Chinese-language databases China Academic Journals Full-text Database (CJFD), Wanfang Data, and Weipu (VIP), were performed. Randomized controlled trials (RCTs) of Bailing capsules in the treatment of NS were included in the meta-analysis. The total effective rate and adverse reaction rate were evaluated with relative risk (RR) and the quantitative data was evaluated with standardized mean difference (SMD) and 95% confidence interval (CI). The quality of the included articles was evaluated using RevMan5.3 software, and the "meta" package of R3.5.1 software was used for all other statistical analysis. RESULTS: A total of 20 papers involving 819 and 824 patients in the treatment group and the control group, respectively, were included. The total effective rate and adverse reaction rate after treatment were reported in 17 and 2 articles, respectively. The total effective rate of the treatment group was 1.22 times that of the control group (I2 =0%, fixed-effects model, 95% CI: 1.16, 1.27), and the adverse reaction rate of the treatment group was 0.22 times that of the control group (I2 =0%, fixed-effects model, 95% CI: 0.08, 0.63). The levels of blood urea nitrogen (BUN) and serum creatinine (SCr) before and after treatment were reported in 15 articles, with SMDs of -0.98 (I2 =50%, fixed-effects model, 95% CI: -1.10, -0.87) and -1.47 (I2 =96%, random-effects model, 95% CI: -2.08, -0.86), respectively. Meanwhile, 13 articles reported the level of 24-hour proteinuria before and after treatment, with an SMD of -1.25 (I2 =92%, fixed effects model, 95% CI: -1.73, -0.78). CONCLUSIONS: For NS patients, treatment with Bailing capsules can achieve higher clinical efficacy and a lower adverse reaction rate than conventional treatment in improving the function of kidney.

Effectiveness of Bailing capsules in the treatment of lupus nephritis: A meta­analysis.

Previous studies have explored the treatment of lupus nephritis with Bailing capsules; however, due to limited sample sizes and inconsistent results across these studies, no definitive conclusions have been drawn. Thus, the present study aimed to provide evidence for the effectiveness of Bailing capsules in the treatment of lupus nephritis. To obtain relevant clinical studies (published before 20 July 2019), PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, WanFang and the Chinese Biomedical Literature Database were searched, and relevant studies concerning the use of Bailing capsules for treating lupus nephritis were selected. The extracted data were general characteristics such as the first author, publication year, study year, follow­up time, age, sex, course of the disease and a number of outcome indicators. These included systemic lupus erythematosus disease activity index (SLEDAI) score, serum albumin (Alb), 24­h urinary protein, serum creatinine, anti­ds­DNAIgM, complement component 3 (C3), and the number of effective treatments and complications. Meta­analysis was performed using R­3.12 software. Publication bias was assessed using Egger's test. A total of 14 studies comprising 1,301 participants were combined for analysis in the present study. The results demonstrated that with the exception of anti­ds­DNAIgM and complement C3, other indicators, such as SLEDAI score, Alb, 24­h urinary protein, serum creatinine, and the number of effective treatments and complications) in the Bailing capsule treatment group were improved compared with those in the control group. The results of the present meta­analysis suggested that Bailing capsules may be effective in the treatment of lupus nephritis.

Comprehensive Optimization of Rehabilitation Measures of Traditional Chinese Medicine to Elderly Patients with COPD at Stable Period / 中国实验方剂学杂志

Objective:To discuss the clinical efficacy of comprehensive optimization of rehabilitation measures of traditional Chinese medicine(TCM) on elderly patients with COPD at stable period, in order to study its effect on immune function and inflammatory factors. Method:One hundred and forty-four patients were randomly divided into control group and observation group by random number table. Patients in control group got ipratropium bromide, 40-80 μg/time, 2-4 times/days, salmeterol roticasone powder, 1 suction/time, 2 times/days, as well as comprehensive western medical treatment measures of healthcare education, oxygen therapy and respiratory muscle exercise. In addition to the basic therapy of ipratropium bromide and salmeterol roticasone powder, patients in observation group was added with syndrome differentiation therapy of TCM, foot bath with TCM and respiratory function exercise with TCM. The course of treatment was 6 months, and 6-month follow-up were recorded. Comprehensive assessment of COPD was recorded. Before and after treatment, respiratory questionnaire (mMRC), self-assessment test for patients with chronic obstructive pulmonary disease (CAT), forced expiratory volume in the first second (FEV1), FEV1%, St George's respiratory questionnaire (SGRQ), 6-minute walking distance (6 MWD) were scored. And levels of CD3+, CD4+, CD8+, CD4+/CD8+, interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha) and hypersensitive C-reactive protein (hs-CRP) were detected. Result:Comprehensive assessment of COPD in the two groups were better than those before treatment (PZ=2.066, Pα were lower than those in control group (P+ was lower than that in control group (P1 and FEV1% were higher than those in control group (P+, CD4+, CD4+/CD8+ and 6-minute walking distance were more than those in control group (PConclusion:Comprehensive optimization of rehabilitation measures in TCM can inhibit inflammatory factors, improve immune function, alleviate clinical symptoms, improve lung function, improve exercise endurance and quality of life of patients, and promote the lung rehabilitation.

Effect of Bailing capsule combined with respiratory rehabilitation training on chronic obstructive pulmonary disease and its influence on blood gas index and pulmonary function of patients / 中国现代医生

Objective To investigate the efficacy of Bailing capsule combined with respiratory rehabilitation training in the treatment of chronic obstructive pulmonary disease and its influence on blood gas index and lung function. Methods70 patients with chronic obstructive pulmonary disease admitted in our department from July 2016 to July 2018 were enrolled in the study. They were divided into groups by parity method. The control group received comprehensive treatments such as sputum and anti-infection. The patients in the experimental group underwent Bailing capsules combined with respiratory rehabilitation training. The efficacy was compared. Results The tatal treatment efficiency rate of the experimental group was 94.29％, which was higher than that of the control group (74.29％). After treatment, the blood gas index and lung function level of the two groups were improved. The blood gas index and lung function level of the experimental group were significantly better than those of the control group, and the difference was statistically significant (P <0.05). Conclusion Bailing capsule combined with respiratory rehabilitation training is effective in treating chronic obstructive pulmonary disease, which can effectively improve the treatment efficiency and improve blood gas index and lung function.

Effect of Bailing capsule on the patients with stable chronic obstructive pulmonary disease / 新乡医学院学报

Objective To investigate the effect and mechanism of Bailing capsule on the patients with stable chronic obstructive pulmonary disease (COPD).Methods A total of 100 patients with more than two weeks of stable COPD were selected from January 2013 to June 2016 in the Department of Respiratory Medicine,the First Affiliated Hospital of Xinxiang Medical University.The patients were randomly divided into the control group and the observation group,with 50 cases in each group.The patients in the control group were treated with tiotropium bromide powder for inhalation,and the patients in the observation group were treated with Bailing capsule orally on the basis of tiotropium bromide powder for inhalation,the patients in the two groups were treated for 12 months.The clinical effect and the average number of acute exacerbations within one year were compared between the two groups;and the level of serum amyloid A (SAA) were compared between the two groups before treatment and 3,6 and 12 months after treatment.Results The total effective rate in the observation group (84.0％) was significantly higher than that in the control group (72.0％)after 12 months of treatment (x2 =4.097,P ＜ 0.05).The average number of acute exacerbations in the observation group within one year was significantly less than that in the control group (P ＜ 0.01).There was no significant difference in serum SAA level between the two groups before treatment and 3 months after treatment (P ＞ 0.05).The serum SAA level in the observation group was significantly lower than that in the control group at the time points of 6 and 12 months after treatment (P ＜ 0.05).There was no significant difference in serum SAA level between before treatment and 3 months after treatment in the two groups (P ＞ 0.05).The serum SAA level at 6 and 12 months after treatment was significantly lower than that before treatment and 3 months after treatment in the two groups (P ＜ 0.05).The serum SAA level at 12 months of treatment was significantly lower than that at 6 months of treatment in the two groups (P ＜ 0.05).Conclusion Bailing capsule can inhibit the inflammatory reaction of COPD patients by interfering with the secretion of serum SAA,so as to improving the clinical manifestations of COPD patients and reducing the acute attack of COPD.

Alprostadil Combined with Bailing Capsule in the Treatment of 46 Case of Early Stage Chronic Kidney Disease / 医药导报

Objective To explore the efficacy of alprostadil combined with Bailing capsule in the treatment of early chronic kidney disease. Methods A total of 94 early stage chronic kidney disease patients were selected and divided into treatment group(n=46) and control group(n=48).The patients in control group were treated with Bailing capsule,5 capsules, tid,po.The patients in treatment group were treated with Bailing capsule combined with 2 mL alprostadil in 20 mL 0.9% sodium chloride injection,intravenous injection,qd.The patients were treated for 4 weeks as a course of treatment in both groups.After 2 courses of treatment,the improvement of renal function,the changes in cytokine levels including NK cells and T cell subsets CD+3, CD+4,CD+8,adverse reactions of two groups were observed. Results The effective rates of the control group and the treatment group were 60.42%,91.30%,respectively(P<0.05).The renal function index 24 h urine protein were(1.15± 0.35) g,serum creatinine were(78.52±10.63) μmol·L-1,urea nitrogen were(8.23±1.65) mmol·L-1,all of which were decreased significantly (P<0.05).The levels of NK cells were(21.89±2.73)%,T cell subsets CD+3were(71.02±5.61)%,CD+4were(38.84±3.52)%, CD+4/CD+8were(1.28 ± 0.14),which were increased significantly,while the level of CD+8were(30.21± 3.03)% was decreased significantly(P<0.05).There was no significant difference between two groups in the adverse reactions(P>0.05). Conclusion The combination of alprostadil and Bailing capsule is effective to early stage chronic kidney disease by improving the renal function and regulating the level of cytokines.

Effect of Bailing capsule on myocardial fibrosis and TGF-β1-MAPK/ERK pathway of viral myocarditis rats / 中国免疫学杂志

Objective:To investigate the effect of Bailing capsule on myocardial fibrosis in mice with viral myocarditis(VMC) and TGF-β1-MAPK/ERK pathway. Methods:Male BALB/c mice ( n=200 ) were randomly divided into model group ( n=180 ) and control group(n=20). The model group mice were infected with Coxsackie virus B3 to prepare VMC myocardial fibrosis. The control group mice were injected with Eagle′s MEM without virus. The model was successful after two months. The survival mice were randomly divided into model group and high,middle and low dose of Bailing capsule was administered consecutively for sixty days,once a day, Cardiac ultrasound was used to test LVEDd,LVEDs,then calculate FS. The expression of type Ⅰ collagen and type Ⅲ collagen in all the mice myocardial tissue was detected by immunohistochemical methods. Masson staining for myocardial fibrosis was used to calculate the collagen volume fraction( CVF) . Western blot was used to detect the protein expression of TGF-β1 and p-ERK1/2. Results:①Compared with the control group,the CVF,typeⅠcollagen and typeⅢcollagen obviously increased,LVEDd,LVEDs increased,FS de-creased,which had statistically significance(P<0. 05).②Compared with the control group,the model group of mice had a statistically significantly higher expression of TGF-β1 and p-ERK1/2(P<0. 05).③Compared with the model group,the expression of CVF,typeⅠcollagen and type Ⅲ collagen of high and middle dose of Bailing capsule was significantly lower,LVEDd,LVEDs decreased,while FS increased(P<0. 05).④Compared with the model group,the high dose of Bailing capsule group of mice had a statistically significantly lower expression of TGF-β1 and p-ERK1/2 ( P<0. 05 ) . Conclusion:①Bailing capsule can prevent myocardial fibrosis of mice with VMC.②The activation of TGF-β1-MAPK/ERK pathway may can promote myocardial fibrosis in VMC.③Bailing capsule could prevent myocardial fibrosis,which may be related to prevention of TGF-β1-MAPK/ERK pathway.

Effect of Bailing capsule on myocardial fibrosis and TGF-β1-MAPK/ERK pathway of viral myocarditis rats / 中国免疫学杂志

Objective:To investigate the effect of Bailing capsule on myocardial fibrosis in mice with viral myocarditis(VMC) and TGF-β1-MAPK/ERK pathway. Methods:Male BALB/c mice ( n=200 ) were randomly divided into model group ( n=180 ) and control group(n=20). The model group mice were infected with Coxsackie virus B3 to prepare VMC myocardial fibrosis. The control group mice were injected with Eagle′s MEM without virus. The model was successful after two months. The survival mice were randomly divided into model group and high,middle and low dose of Bailing capsule was administered consecutively for sixty days,once a day, Cardiac ultrasound was used to test LVEDd,LVEDs,then calculate FS. The expression of type Ⅰ collagen and type Ⅲ collagen in all the mice myocardial tissue was detected by immunohistochemical methods. Masson staining for myocardial fibrosis was used to calculate the collagen volume fraction( CVF) . Western blot was used to detect the protein expression of TGF-β1 and p-ERK1/2. Results:①Compared with the control group,the CVF,typeⅠcollagen and typeⅢcollagen obviously increased,LVEDd,LVEDs increased,FS de-creased,which had statistically significance(P<0. 05).②Compared with the control group,the model group of mice had a statistically significantly higher expression of TGF-β1 and p-ERK1/2(P<0. 05).③Compared with the model group,the expression of CVF,typeⅠcollagen and type Ⅲ collagen of high and middle dose of Bailing capsule was significantly lower,LVEDd,LVEDs decreased,while FS increased(P<0. 05).④Compared with the model group,the high dose of Bailing capsule group of mice had a statistically significantly lower expression of TGF-β1 and p-ERK1/2 ( P<0. 05 ) . Conclusion:①Bailing capsule can prevent myocardial fibrosis of mice with VMC.②The activation of TGF-β1-MAPK/ERK pathway may can promote myocardial fibrosis in VMC.③Bailing capsule could prevent myocardial fibrosis,which may be related to prevention of TGF-β1-MAPK/ERK pathway.

Effects of low molecular weight heparin calcium combined with Bailing capsule in treatment of children with Henoch-Schonlein purpura nephritis and the efficacy of hs-CRP, MMP-9, APN and CysC / 中国生化药物杂志

Objective To study the effect of low molecular weight heparin calcium combined with Bailing capsule in treatment of children with Henoch-Schonlein purpura nephritis and the efficacy of serum hs-CRP, MMP-9, APN and CysC.MethodsFrom January 2013 to December 2015, 84 children with Henoch-Schonlein purpura nephritis were enrolled in our hospital.According to the order of admission, the observation group and control group were divided into observation group and control group.The control group were given low molecular weight heparin calcium, the observation group were treated with low molecular weight heparin calcium combined with Bailing capsule for treatment.The levels of serum hs-CRP, MMP-9, APN, CysC, inflammatory factors and immune levels were observed in the two groups.ResultsAfter treatment, the clinical effective rate of the observation group was significantly higher than that of the control group[92.86% (39/42) vs 69.05% (29/42)] (P<0.05).There were no significant differences in hs-CRP, MMP-9, APN and CysC levels between the two groups.After treatment, the levels of hs-CRP, MMP-9 and CysC in the two groups were significantly higher than those before treatment (P<0.05).APN was significantly higher than that before treatment (P<0.05).Compared with the control group, the levels of hs-CRP, MMP-9 and CysC in the observation group were lower than those in the control group (P<0.05), and the APN level was lower than that in the control group (P<0.05).There were no significant differences in TNF-α, IL-6, IL-10 and IL-18 levels between the two groups before treatment.After treatment, The levels of TNF-α, IL-6 and IL-18 in the two groups were significantly lower than those before treatment (P<0.05).There were no significant differences in IgA, IgG and IgM levels between the two groups.After treatment, the levels of IgA, IgG and IgM in the two groups were significantly lower than those before treatment (P<0.05).The levels of IgA, IgG and IgM in the observation group were lower than those in the control group (P<0.05).There was no significant difference in adverse reaction rate between the two groups.ConclusionLow molecular weight heparin combined with Bailing capsule can effectively reduce hs-CRP, MMP-9, CysC level and APN level in children with Henoch-Schonlein purpura nephritis, improve clinical symptoms, good clinical efficacy and high safety.

Effect of treatment and intervention on COPD in stable phase with chronic obstructive pulmonary disease / 中国生化药物杂志

Objective To investigate the analysis of Symbicort in stable stage of chronic obstructive pulmonary disease treatment and intervention. Methods 80 patients with chronic obstructive pulmonary disease in stable period from June 2014-2016 year in May in our hospital were randomly divided into control group and experimental group, 40 cases in each group. The control group of patients with the use of simple Symbicort treatment and routine nursing care to patients, patients in the experimental group using Symbicort combined with Bailing Capsule for treatment, and the implementation of targeted nursing intervention measures, compare the effect of two groups of patients and nursing satisfaction. Results the clinical treatment of patients in the experimental group the total efficiency 95.0%, nursing satisfaction was 97.5%, the control of clinical patients in the treatment group the total effective rate was 80.0%, nursing satisfaction was 87.5%, the experimental group was significantly higher than the control group, the difference was statistically significant (P<0.05). Conclusion Chronic In the stable period of obstructive pulmonary disease, the combination of Xin Yi capsule combined with Bailing capsule can effectively improve the pulmonary function of patients and improve the clinical therapeutic effect, and is worthy of popularization and application in clinic.

Influence of Bailing capsule on the serum levels of hs-CRP, IL-18, TNF-α in patients with chronic kidney disease / 中国基层医药

Objective To observe the influence of Bailing capsule on the serum levels of hs-CRP,IL-18,TNF-α in patients with chronic kidney disease (CKD).Methods According to the digital table,56 CKD patients were randomly divided into the control group(28 cases) and treatment group(treated with Bailing capsules,28 cases).Meanwhile,20 healthy adults were selected as the normal controls.The blood concentrations of hs-CRP,IL-18,TNF -α,Scr and BUN were determined.Results The levels of hs-CRP,IL-18,TNF-α,Scr and BUN in CKD patients were significantly higher than those in the normal control [(5.99 ± 2.67) mg/L,(6.17-± 2.23) mg/L vs.(2.27 ± 2.16) mg/L,(44.43 ± 7.54)μg/L,(46.54 ± 8.63)μg/L vs.(11.42 ± 3.32) μg/L,(95.22 ± 34.65) ng/L,(105.48 ± 33.25) ng/L vs.(21.34-± 10.10) ng/L,(6.86 ± 2.97) mmol/L,(6.89 ± 2.85) mmol/L vs.(5.32 ±2.43) mmol/L,(98.47 ± 28.85) μmol/L,(95.46 ± 27.83) μmol/L vs.(75.45 ± 28.20)μmol/L,all P ＜ 0.05].The levels of hs-CRP,IL-18,TNF-α,Scr and BUN decreased after 12 weeks of conventional treatment (t =-0.22,-1.30,-1.76,-0.67,-1.16,all P ＞0.05),while those were significantly decreased with Bailing capsule treatment (t =-2.77,-3.81,-4.71,-2.06,all P ＜ 0.05).Conclusion The renal inflammation can be alleviated by Bailing capsule in CKD patients,which can slow the progression of CKD.

Analysis of Bailing capsule combined losartan for UMA and lipid metabolism in patients with early diabetic nephropathy / 中国生化药物杂志

Objective To study the Bailing capsule combined losartan for UMA and lipid metabolism in patients with early diabetic nephropathy impact analysis.Methods 118 patients with early diabetic nephropathy from October 2015 to May 2016 in our hospital, according to the random lottery was divided into observation group and control group, control group using losartan treatment, observation group on the basis of the combination of Bailing capsule for treatment.Two groups of patients were treated after 3 months, observing two groups of patients with UMA and lipid metabolism related situation, and analyzes the effect of the treatment.Results The UMA ( 125.00 ±44.00 ) mg/24 h and UAER ( 54.64 ±17.31 )μg/min were significantly lower in the observation group than in the control group UMA (216.00 ±46.00) mg/24 h, UAER (67.42 ±21.86) μg/min, 2 group difference was statistically significant (P<0.05).The total cholesterol (TC) of the observation group was (6.15 ±0.75) mmol/L, triglyceride (TG) was (2.34 ±0.48) mmol/L, low density lipoprotein (LDL-C) was (3.55 ±0.73) mmol/L.The levels of TC (6.74 ±0.78) mmol /L, TG (3.01 ± 0.41) mmol/L and LDL-C (4.06 ±0.64) mmol/L, respectively.The levels of TC, TG and LDL-C in the observation group were significantly lower than those in the control group, and high-density lipoprotein (HDL-C) (1.39 ±0.26)mmol/L was significantly higher than that in the control group (1.26 ±0.42) mmol/L, the difference was statistically significant (P<0.05); Two groups of patients after treatment, the observation group total effective rate was 89.7%, significantly higher than that of control group total effective rate 75.0%, two groups are significant difference (P<0.05). Conclusion Bailing capsule combined losartan treatment of early diabetic nephropathy , can effectively reduce the levels of UMA, improve blood lipid in patients with blood sugar levels, which has significant therapeutic effect.

Study on effect of Bailing Capsule combined with Xihuangwan on estrogen receptor,matrix metalloproteinase-9, tumor markers and estrogen in stage III breast cancer patients / 中国生化药物杂志

Objective To investigate effect of Bailing Capsule combined with Xihuangwan in stage III breast cancer patients of ER, MMP-9, tumor markers and estrogen.Methods 76 Patients with stage III breast cancer were selected and divided into control group anf experiment group.Control group were treated by clinical routine method.Experiment group were treated on the base of the control group with Bailing Capsule combined with Xihuangwan.The ER, MMP-9, tumor markers, estrogen, survival time and quality of life were observed and compared.ResuIts Compared with control group, the survival period of the experiment group were longer(P<0.05),the quality of life score were higher(P<0.05),the ER, MMP-9, E2, E1 level and the serum levels of CA15-3, CA125 and CEA were lower(P<0.05).ConcIusion Bailing capsule combined with Xihuang Pill can effectively reduce stage III breast cancer tumor marker levels, decrease the ER, the expression of MMP-9 and estrogen level and prolong survival time, improve the quality of life, has the vital significance to the clinical therapy for stage III breast cancer.

Curative effects of valsartan combined with Bailing capsule for the treatment of diabetic nephropathy / 中国基层医药

Objective To discuss the curative effects and clinical safety of using valsartan combined with Bailing capsule to treat diabetic nephropathy ( DN) .Methods In our hospital ,90 patients with diabetic nephropathy were chosen and divided into the two groups ( 45 cases in each group ):the control group treated with 80mg/d of valsartan and the observation group given bailing capsules 9g/d on basis of the control group .Before and after 16 weeks treatment,two groups′24h urine trace albumin excretion rate (UAER),potassium,serum creatinine (SCr), urea nitrogen ( BUN) ,total cholesterol ( TC) ,triglycerides ( TG) ,fasting plasma glucose ( FPG) and blood rheology changes were recorded and compared .Results After treatment the observation group′s high shear viscosity ,low shear viscosity,whole blood reductive viscosity and blood plasma viscosity all significantly decreased ( t=6.236,10.659, 12.509 and 7.269,all P0.05);No adverse reactions such as heart ,liver and kidney happened in the two groups .Conclusion Using valsartan in joint with Bailing capsule for the treatment of diabetic nephropathy ( DN) has distinct curative effects and no obvious adverse reactions ,which is worthy of clinical promotion .